urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2022-10-4-13-20urovest-621Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESРоль экспрессии переносчика глюкозы первого типа (GLUT1) и карбоновой ангидразы 9 типа (CAIX) тканью аденокарциномы простаты в определении прогноза заболевания и эффективности радикального леченияThe role of glucose transporter type 1 (GLUT1) and carbonic anhydrase IX (CAIX) expression by prostate adenocarcinoma tissue in determining disease prognosis and effectiveness of radical treatmenthttps://orcid.org/0000-0001-6606-147XВовденкоС. В.VovdenkoS. V.

Вовденко Станислав Викторович — аспирант Института урологии и репродуктивного здоровья человека Сеченовского Университета.

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Stanislav V. Vovdenko — M.D., Postgrad. Student, Institute for Urology and Reproductive health (Sechenov University).

8 bld. 2 Trubetskaya St., Moscow, 119991

vovdenkostanislav@yandex.ruМорозовА. О.MorozovA. O.

Морозов Андрей Олегович — кандидат медицинских наук, старший научный сотрудник Института урологии и репродуктивного здоровья человека Сеченовского Университета.

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Andrei O. Morozov — Cand. Sc.(Med), Senior Researcher, Institute for Urology and Reproductive health (Sechenov University).

8 bld. 2 Trubetskaya St., Moscow, 119991

andrei.o.morozov@gmail.comhttps://orcid.org/0000-0001-9704-5915АвраамоваС. Т.AvraamovaS. T.

Авраамова София Тариэловна — кандидат медицинских наук, доцент Института клинической морфологии и цифровой патологии Сеченовского Университета.

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Sophia T. Avraamova — Cand.Sc.(Med), Assoc. Prof. (Docent), Institute for Morphology and Digital Pathology (Sechenov University).

8 bld. 2 Trubetskaya St., Moscow, 119991

avraamovast@mail.ruhttps://orcid.org/0000-0002-2519-6420АлександровН. С.AlexandrovN. S.

Александров Николай Сергеевич — кандидат медицинских наук, доцент Института клинической морфологии и цифровой патологии Сеченовского Университета.

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Nikolai S. Alekssandrov — Cand.Sc.(Med), Assoc.Prof. (Docent), Institute for Morphology and Digital Pathology (Sechenov University).

8 bld. 2 Trubetskaya St., Moscow, 119991

dr.klauss@mail.ruhttps://orcid.org/0000-0001-7183-0456ЖарковН. В.ZharkovN. V.

Жарков Николай Владимирович — кандидат биологических наук, старший лаборант Института клинической морфологии и цифровой патологии Сеченовского Университета.

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Nikolai V. Zharkov — Cand.Sc.(Biol), Senior Laboratory Assistant, Institute for Morphology and Digital Pathology (Sechenov University).

8 bld. 2 Trubetskaya St., Moscow, 119991

nickzharkov@mail.ruhttps://orcid.org/0000-0003-3941-2742КозловВ. В.KozlovV. V.

Козлов Василий Владимирович — кандидат медицинских наук, доцент кафедры общественного здоровья и здравоохранения им. Н.А. Семашко Сеченовского Университета.

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Vasilii V. Kozlov — Cand.Sc.(Med), Assoc. Prof.(Docent), Semashko Dept. of Public Health and Healthcare (Sechenov University).

8 bld. 2 Trubetskaya St., Moscow, 119991

kvv.doc@mail.ruhttps://orcid.org/0000-0002-1107-3753КоганЕ. А.KoganE. A.

Коган Евгения Алтаровна — доктор медицинских наук, профессор Института клинической морфологии и цифровой патологии Сеченовского Университета.

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Evgeniia A. Kogan — Dr.Sc.(Med), Prof., Institute for Morphology and Digital Pathology (Sechenov University).

8 bld. 2 Trubetskaya St., Moscow, 119991

koganevg@gmail.comhttps://orcid.org/0000-0002-2746-5962БезруковЕ. А.BezrukovE. A.

Безруков Евгений Алексеевич — доктор медицинских наук, профессор Института урологии и репродуктивного здоровья человека Сеченовского Университета.

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Evgenii A. Bezrukov — Dr.Sc.(Med), Prof., Institute for Urology and Reproductive Health (Sechenov University).

8 bld. 2 Trubetskaya St., Moscow, 119991

eabezrukov@rambler.ruПервый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation2022261220221041320Copyright © Вовденко С.В., Морозов А.О., Авраамова С.Т., Александров Н.С., Жарков Н.В., Козлов В.В., Коган Е.А., Безруков Е.А., 20232023Вовденко С.В., Морозов А.О., Авраамова С.Т., Александров Н.С., Жарков Н.В., Козлов В.В., Коган Е.А., Безруков Е.А.Vovdenko S.V., Morozov A.O., Avraamova S.T., Alexandrov N.S., Zharkov N.V., Kozlov V.V., Kogan E.A., Bezrukov E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/621Введение

Введение. Сегодня вследствие недостаточной диагностической точности имеющихся инструментов определения клинически значимых форм рака простаты является актуальным поиск новых показателей, позволяющих спрогнозировать течение заболевания и эффективность радикального лечения. Учитывая характерную для многих высокозлокачественных опухолей способность к повышенному потреблению глюкозы, активному росту и развитию в условиях гипоксии, перспективной представляется оценка уровня экспрессии переносчика глюкозы 1 типа (GLUT1) и карбонической ангидразы 9 типа (CAIX) в клетках аденокарциномы простаты различной степени злокачественности.

Цель исследования

Цель исследования. Определить степень экспрессии CAIX и GLUT1 клетками аденокарциномы простаты различной степени злокачественности для оценки прогноза заболевания и эффективности радикальной простатэктомии.

Материалы и методы

Материалы и методы. Проведено иммуногистохимическое исследование послеоперационного материала пациентов после радикальной простатэктомии с определением экспрессии GLUT1 и CAIX опухолевыми клетками. Определён факт наличия или отсутствия биохимического рецидива заболевания в течение года после операции. Определён уровень корреляции между степенью экспрессии данных маркеров, фактом наличия биохимического рецидива и рядом других клинических параметров.

Результаты

Результаты. Степень экспрессии GLUT1 статистически значимо прямо коррелировала со степенью злокачественности ISUP 4 и ISUP 5 (r = 0,457, p < 0,0001), уровнем простат-специфического антигена (ПСА) (r = 0,378, p < 0,0001), стадией заболевания pT3b (r = 0,380, p < 0,0001), экстракапсулярным распространением опухоли (r = 0,355, p = 0,001), а также обратно коррелировала со степенью злокачественности ISUP 1 (r = -0,274, p = 0,009). Иммуноэкспрессия CAIX наблюдалась лишь в 10,0% образцов и обладала низкой выраженностью (< 20% клеток).

Заключение

Заключение. Повышенная иммуноэкспрессия переносчика глюкозы 1 типа (GLUT1) клетками аденокарциномы простаты среди пациентов после радикальной простатэктомии ассоциирована с высокой степенью злокачественности (ISUP 4 и 5), стадией заболевания pT3, морфологически подтверждённым экстракапсулярным распространением опухоли, а также высокими значениями ПСА, что позволяет использовать её для оценки прогноза течения заболевания.

Introduction

Introduction. Today, due to the insufficient diagnostic accuracy of existing tools for determining clinically significant forms of prostate cancer, the search for new indicators that predict the course of the disease and the effectiveness of radical treatment is relevant. Various malignant tumors could increase glucose consumption and grow under hypoxic conditions. It seems promising to assess the expression level of glucose transporter type 1 (GLUT1) and carbonic anhydrase IX (CAIX) in prostate adenocarcinoma cells of different malignancy score.

Objective

Objective. To determine CAIX and GLUT1 expression in ISUP grades 1-5 prostate adenocarcinoma cells for evaluation of the disease prognosis and radical prostatectomy effectiveness.

Materials and methods

Materials and methods. Immunohistochemical study of postoperative material after radical prostatectomy with determination of GLUT1 and CAIX expression by tumor cells was carried out. The presence or absence of biochemical recurrence within one year after surgery was determined. The correlation between the level of expression, the presence of biochemical relapse and a few other clinical parameters was determined.

Results

Results. GLUT1 expression level statistically significant correlated with ISUP 4 and 5 (r = 0.457, p < 0.0001), prostate-specific antigen (PSA) level (r = 0.378, p < 0.0001), pT3b disease stage (r = 0.380, p < 0.0001), extracapsular extension (r = 0.355, p = 0.001), and inversely correlated with ISUP 1 (r = -0.274, p = 0.009). CAIX immunoexpression was observed in 10.0% of samples and the intensity was low (< 20% of cells).

Conclusion

Conclusion. Elevated expression of glucose transporter type 1 (GLUT1) by prostate adenocarcinoma cells among patients after radical prostatectomy is associated with high grade of malignancy (ISUP 4 and 5), pT3b disease stage, extracapsular extension of the tumor, as well as high PSA, which allows using it for the prognosis evaluation.

простатарак простатыпростатэктомияprostateprostate cancerradical prostatectomyReferencesLoeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046-55. https://doi.org/10.1016/j.eururo.2013.12.062Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046-55. https://doi.org/10.1016/j.eururo.2013.12.062Catalona WJ. Prostate Cancer Screening. Med Clin North Am. 2018;102(2):199-214. https://doi.org/10.1016/j.mcna.2017.11.001Catalona WJ. Prostate Cancer Screening. Med Clin North Am. 2018;102(2):199-214. https://doi.org/10.1016/j.mcna.2017.11.001Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int. 2010;105(1):8-13. https://doi.org/10.1111/j.1464-410X.2009.08921.xStewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int. 2010;105(1):8-13. https://doi.org/10.1111/j.1464-410X.2009.08921.xMeziou S, Ringuette Goulet C, Hovington H, Lefebvre V, Lavallée É, Bergeron M, Brisson H, Champagne A, Neveu B, Lacombe D, Beauregard JM, Buteau FA, Riopel J, Pouliot F. GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome. Prostate Cancer Prostatic Dis. 2020;23(3):441-448. https://doi.org/10.1038/s41391-020-0202-xMeziou S, Ringuette Goulet C, Hovington H, Lefebvre V, Lavallée É, Bergeron M, Brisson H, Champagne A, Neveu B, Lacombe D, Beauregard JM, Buteau FA, Riopel J, Pouliot F. GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome. Prostate Cancer Prostatic Dis. 2020;23(3):441-448. https://doi.org/10.1038/s41391-020-0202-xCostello LC, Feng P, Milon B, Tan M, Franklin RB. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis. 2004;7(2):111-7. https://doi.org/10.1038/sj.pcan.4500712Costello LC, Feng P, Milon B, Tan M, Franklin RB. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis. 2004;7(2):111-7. https://doi.org/10.1038/sj.pcan.4500712Costello LC, Franklin RB, Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion. 2005;5(3):143-53. https://doi.org/10.1016/j.mito.2005.02.001Costello LC, Franklin RB, Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion. 2005;5(3):143-53. https://doi.org/10.1016/j.mito.2005.02.001Pértega-Gomes N, Baltazar F. Lactate transporters in the context of prostate cancer metabolism: what do we know? Int J Mol Sci. 2014;15(10):18333-48. https://doi.org/10.3390/ijms151018333Pértega-Gomes N, Baltazar F. Lactate transporters in the context of prostate cancer metabolism: what do we know? Int J Mol Sci. 2014;15(10):18333-48. https://doi.org/10.3390/ijms151018333Franklin RB, Costello LC. Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys. 2007;463(2):211-7. https://doi.org/10.1016/j.abb.2007.02.033Franklin RB, Costello LC. Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys. 2007;463(2):211-7. https://doi.org/10.1016/j.abb.2007.02.033Franz MC, Anderle P, Bürzle M, Suzuki Y, Freeman MR, Hediger MA, Kovacs G. Zinc transporters in prostate cancer. Mol Aspects Med. 2013;34(2-3):735-41. https://doi.org/10.1016/j.mam.2012.11.007Franz MC, Anderle P, Bürzle M, Suzuki Y, Freeman MR, Hediger MA, Kovacs G. Zinc transporters in prostate cancer. Mol Aspects Med. 2013;34(2-3):735-41. https://doi.org/10.1016/j.mam.2012.11.007Fraum TJ, Ludwig DR, Kim EH, Schroeder P, Hope TA, Ippolito JE. Prostate cancer PET tracers: essentials for the urologist. Can J Urol. 2018;25(4):9371-9383. PMID: 30125515Fraum TJ, Ludwig DR, Kim EH, Schroeder P, Hope TA, Ippolito JE. Prostate cancer PET tracers: essentials for the urologist. Can J Urol. 2018;25(4):9371-9383. PMID: 30125515Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202(3):654-62. https://doi.org/10.1002/jcp.20166Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202(3):654-62. https://doi.org/10.1002/jcp.20166Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 2003;97(8):2035-42. https://doi.org/10.1002/cncr.11293Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 2003;97(8):2035-42. https://doi.org/10.1002/cncr.11293Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, Godoy A. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem. 2012;113(2):553-62. https://doi.org/10.1002/jcb.23379Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, Godoy A. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem. 2012;113(2):553-62. https://doi.org/10.1002/jcb.23379Xiao H, Wang J, Yan W, Cui Y, Chen Z, Gao X, Wen X, Chen J. GLUT1 regulates cell glycolysis and proliferation in prostate cancer. Prostate. 2018;78(2):86-94. https://doi.org/10.1002/pros.23448Xiao H, Wang J, Yan W, Cui Y, Chen Z, Gao X, Wen X, Chen J. GLUT1 regulates cell glycolysis and proliferation in prostate cancer. Prostate. 2018;78(2):86-94. https://doi.org/10.1002/pros.23448Gonzalez-Menendez P, Hevia D, Alonso-Arias R, Alvarez-Artime A, Rodriguez-Garcia A, Kinet S, Gonzalez-Pola I, Taylor N, Mayo JC, Sainz RM. GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress. Redox Biol. 2018;17:112-127. https://doi.org/10.1016/j.redox.2018.03.017Gonzalez-Menendez P, Hevia D, Alonso-Arias R, Alvarez-Artime A, Rodriguez-Garcia A, Kinet S, Gonzalez-Pola I, Taylor N, Mayo JC, Sainz RM. GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress. Redox Biol. 2018;17:112-127. https://doi.org/10.1016/j.redox.2018.03.017Wang J, Xu W, Wang B, Lin G, Wei Y, Abudurexiti M, Zhu W, Liu C, Qin X, Dai B, Wan F, Zhang H, Zhu Y, Ye D. GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Lett. 2020;485:45-55. https://doi.org/10.1016/j.canlet.2020.05.007Wang J, Xu W, Wang B, Lin G, Wei Y, Abudurexiti M, Zhu W, Liu C, Qin X, Dai B, Wan F, Zhang H, Zhu Y, Ye D. GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Lett. 2020;485:45-55. https://doi.org/10.1016/j.canlet.2020.05.007Garlapati C, Joshi S, Turaga RC, Mishra M, Reid MD, Kapoor S, Artinian L, Rehder V, Aneja R. Monoethanolamine-induced glucose deprivation promotes apoptosis through metabolic rewiring in prostate cancer. Theranostics. 2021;11(18):9089-9106. https://doi.org/10.7150/thno.62724Garlapati C, Joshi S, Turaga RC, Mishra M, Reid MD, Kapoor S, Artinian L, Rehder V, Aneja R. Monoethanolamine-induced glucose deprivation promotes apoptosis through metabolic rewiring in prostate cancer. Theranostics. 2021;11(18):9089-9106. https://doi.org/10.7150/thno.62724Cannistraci A, Hascoet P, Ali A, Mundra P, Clarke NW, Pavet V, Marais R. MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer. Oncogene. 2022;41(10):1445-1455. https://doi.org/10.1038/s41388-022-02178-0Cannistraci A, Hascoet P, Ali A, Mundra P, Clarke NW, Pavet V, Marais R. MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer. Oncogene. 2022;41(10):1445-1455. https://doi.org/10.1038/s41388-022-02178-0Gasinska A, Jaszczynski J, Rychlik U, Łuczynska E, Pogodzinski M, Palaczynski M. Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy. Pathol Oncol Res. 2020;26(2):1049-1056. https://doi.org/10.1007/s12253-019-00659-4Gasinska A, Jaszczynski J, Rychlik U, Łuczynska E, Pogodzinski M, Palaczynski M. Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy. Pathol Oncol Res. 2020;26(2):1049-1056. https://doi.org/10.1007/s12253-019-00659-4Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle. 2004;3(2):164-7. PMID: 14712082Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle. 2004;3(2):164-7. PMID: 14712082Parkkila S. Significance of pH regulation and carbonic anhydrases in tumour progression and implications for diagnostic and therapeutic approaches. BJU Int. 2008;101 Suppl 4:16-21. https://doi.org/10.1111/j.1464-410X.2008.07643.xParkkila S. Significance of pH regulation and carbonic anhydrases in tumour progression and implications for diagnostic and therapeutic approaches. BJU Int. 2008;101 Suppl 4:16-21. https://doi.org/10.1111/j.1464-410X.2008.07643.xSmyth LG, O'Hurley G, O'Grady A, Fitzpatrick JM, Kay E, Watson RW. Carbonic anhydrase IX expression in prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(2):178-81. https://doi.org/10.1038/pcan.2009.58Smyth LG, O'Hurley G, O'Grady A, Fitzpatrick JM, Kay E, Watson RW. Carbonic anhydrase IX expression in prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(2):178-81. https://doi.org/10.1038/pcan.2009.58Donato DP, Johnson MT, Yang XJ, Zynger DL. Expression of carbonic anhydrase IX in genitourinary and adrenal tumours. Histopathology. 2011;59(6):1229-39. https://doi.org/10.1111/j.1365-2559.2011.04074.xDonato DP, Johnson MT, Yang XJ, Zynger DL. Expression of carbonic anhydrase IX in genitourinary and adrenal tumours. Histopathology. 2011;59(6):1229-39. https://doi.org/10.1111/j.1365-2559.2011.04074.xFiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, Nativi C, Richichi B, Scozzafava A, Carta F, Torre E, Supuran CT, Chiarugi P. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle. 2013;12(11):1791-801. https://doi.org/10.4161/cc.24902Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, Nativi C, Richichi B, Scozzafava A, Carta F, Torre E, Supuran CT, Chiarugi P. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle. 2013;12(11):1791-801. https://doi.org/10.4161/cc.24902Ambrosio MR, Di Serio C, Danza G, Rocca BJ, Ginori A, Prudovsky I, Marchionni N, Del Vecchio MT, Tarantini F. Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer. Diagn Pathol. 2016;11(1):45. https://doi.org/10.1186/s13000-016-0495-1Ambrosio MR, Di Serio C, Danza G, Rocca BJ, Ginori A, Prudovsky I, Marchionni N, Del Vecchio MT, Tarantini F. Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer. Diagn Pathol. 2016;11(1):45. https://doi.org/10.1186/s13000-016-0495-1Riemann A, Güttler A, Haupt V, Wichmann H, Reime S, Bache M, Vordermark D, Thews O. Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity. Oncol Res. 2018;26(2):191-200. https://doi.org/10.3727/096504017X14965111926391Riemann A, Güttler A, Haupt V, Wichmann H, Reime S, Bache M, Vordermark D, Thews O. Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity. Oncol Res. 2018;26(2):191-200. https://doi.org/10.3727/096504017X14965111926391

The authors declare that there are no conflicts of interest present.